Micronized Bone Marrow and Niche Preservation: Biological Rationale, Preclinical Evidence, Translational Potential and Limitations

Bone marrow aspirate concentrate (BMAC) has produced inconsistent results in osteoarthritis (OA), with several randomized clinical trials failing to show superiority over saline, hyaluronic acid, or corticosteroid injection. In this Perspective, we propose that these outcomes may reflect, in part, how marrow is harvested and processed rather than an absence of regenerative potential. Aspiration and centrifugation yield a product rich in leukocytes and platelets but poor in mesenchymal stromal cells (MSCs), and do not include marrow’s spatially organized parenchyma—extracellular matrix (ECM), matricellular proteins with their associated extracellular vesicles, growth factors, and cytokines—that specifies cell behavior. We describe BMAX, a niche-preserving, micronized bone marrow parenchyma/stroma product mechanically released from cancellous bone and designed to retain multiple MSC subpopulations, pericytes, hematopoietic progenitors, and megakaryocytes within their native matrix. In a single-donor study in a rat model of post-traumatic knee OA, BMAX significantly reduced pain behavior, improved cartilage regeneration and OARSI scores relative to both vehicle and BMAC, with better regeneration of proteoglycan and type-II collagen staining. Applications beyond OA—including tendon, ligament, intervertebral disk, bone healing, and inflammation-related conditions—are proposed as research hypotheses. The evidence to date is preclinical and hypothesis-generating; it cannot yet separate niche preservation from other differences between the products, and controlled clinical trials are required. If confirmed, the path forward in the treatment of OA, and regenerative medicine in general, may lie less in culture-expanded cell populations or engineering a new cell than in preserving the regenerative unit evolution has already assembled.